Immunogenicity according to reactogenicity of Covid-19 vaccines

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025316

Enrollment

Registered

2021-05-12

Start date

2021-05-17

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination against SARS-CoV-2 Z25.8

Interventions

Group 1: 45 participants with severe vaccine reactions resulting in absence of work. Group 2: 45 participants without vaccine reactions or only minimal on injection side

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: o minimum age 18 years o two doses of BNT 162b2 at intervals of 3-6 weeks o 2nd dose 4-10 weeks before enrolment o informed consent

Exclusion criteria

Exclusion criteria: o no informed consent o no willingness to complete the survey o no history of covid-19

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 antibody level and T-cell response measured with ELISpot 4-10 weeks after 2nd vaccination with BNT162b2.	—

Secondary

Measure	Time frame
survey results (demographic information, vaccine reaction information etc.)	—

Countries

Germany

Contacts

Public ContactStilla Bauernfeind

Universitätsklinikum Regensburg

stilla.bauernfeind@ukr.de0941-944-4250

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026